EUVIMEDEUVIMED entdecken
Crossref

Rational Design of a Novel 6 H -Benzo[ c ]chromen Series as Selective PI3Kα Inhibitors

Xue Shi, Heng Feng, Haigang Tian, Haibiao Ma, Xiaomeng Pang, Chenhan Mao, Peng Xiang, Zhengze Xu, Weidong Han, Yuxiang Yan, Wei Chen, Yuqing Nan und 5 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xue Shi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biobank, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China. Hauptthemen laut MEDLINE: Drug Design, Molecular Docking Simulation, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shaanxi Provincial Science and Technology Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway is a frequently dysregulated pathway in human cancer, and PI3Kα is one of the most frequently mutated kinases in human cancer. A selective PI3Kα inhibitor may provide the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family. Here, we describe our efforts to discover a novel series of selective PI3Kα inhibitors using structure-based drug design and molecular docking to inform the design of 6H-benzo[c]chromen inhibitors. XJTU-L453 (21) was identified with PI3Kα inhibitory potency and unique selectivity over other PI3K isoforms and all other kinases tested. Further evaluation of pharmacokinetic properties and in vivo efficacy led to the identification of the preclinical potential of XJTU-L453 (21).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignMolecular Docking SimulationPhosphoinositide-3 Kinase InhibitorsAnimalsHumansMiceRatsClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsStructure-Activity RelationshipBenzopyrans

Substanzen

Class I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsBenzopyrans

Autor:innen und Institutionen

  • Biobank, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China.
  • Department of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China.
  • Department of Pharmaceutical Analysis, School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China.
  • Clinical Laboratory Center, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States.

ORCID-Profile: Yiping Li

Förderung

  • National Natural Science Foundation of China
  • Shaanxi Provincial Science and Technology Department

Zitieren

APA

Shi, X., Feng, H., Tian, H., Ma, H., Pang, X., Mao, C., Xiang, P., Xu, Z., Han, W., Yan, Y., Chen, W., Nan, Y., Nan, G., Hu, Z., Hui, L., Li, C., & Li, Y. (2024). Rational Design of a Novel 6 H -Benzo[ c ]chromen Series as Selective PI3Kα Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00992

Vancouver

Shi X, Feng H, Tian H, Ma H, Pang X, Mao C, et al. Rational Design of a Novel 6 H -Benzo[ c ]chromen Series as Selective PI3Kα Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00992

BibTeX
@article{Shi2024,
  author = {Shi, Xue and Feng, Heng and Tian, Haigang and Ma, Haibiao and Pang, Xiaomeng and Mao, Chenhan and Xiang, Peng and Xu, Zhengze and Han, Weidong and Yan, Yuxiang and Chen, Wei and Nan, Yuqing and Nan, Guanjun and Hu, Zhenyue and Hui, Lingyun and Li, Chenglong and Li, Yiping},
  title = {Rational Design of a Novel 6 H -Benzo[ c ]chromen Series as Selective PI3Kα Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00992}
}
Kostenlos starten →